-
Mashup Score: 2Immune evasiveness of SARS-CoV-2 variants and vaccine selection - 15 hour(s) ago
The constant transformation of SARS-CoV-2 poses considerable challenges for COVID-19 vaccine programmes. Since it was first detected in August, 2023, the SARS-CoV-2 omicron subvariant BA.2.86, and in particular the sublineage JN.1, have rapidly spread around the world. Compared with the subvariant XBB, BA.2.86 has more than 30 mutations in the spike protein, and its descendant JN.1 harbours an additional crucial mutation, Leu455Ser, in the angiotensin-converting enzyme 2 binding domain.1,2 WHO classified JN.1 as a variant of interest shortly after its detection, and justified concern has been raised about whether the XBB.1.5 updated vaccine would provide effective protection against this new subvariant.
Source: www.thelancet.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 38
Compared with other SARS-CoV-2 variants, BA.2.86 and the JN.1 sublineage were less sensitive to vaccine-induced immune protection from the XBB.1.5 updated COVID-19 vaccine; however, we found no evidence that infection with BA.2.86 or JN.1 resulted in increased disease severity or different symptom profiles. Although less effective against the new variants, XBB.1.5 vaccination remains protective and reduces the risk of infection and COVID-19 disease.
Source: www.thelancet.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 9
With two endorsed and prophylactic vaccines against Zaire ebolavirus (referred to hereafter as EBOV), the number of individuals vaccinated against EBOV worldwide is estimated to range between 500 000 and 1 000 000 individuals, increasing with every renewed EBOV threat and vaccination campaign. Therefore, re-exposure of previously vaccinated health-care workers, and possibly community members, could become more frequent. In the absence of long-term data on vaccine efficacy and duration of protection, we urgently need to understand revaccination strategies that could maximise the level of protection.
Source: www.thelancet.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 34Evaluation of a single-dose HPV vaccine strategy for promoting vaccine, health, and gender equity - 8 day(s) ago
Although several countries have adopted a single-dose human papillomavirus (HPV) vaccination strategy, many other countries continue to include multiple doses in their vaccination programmes. There are ethical reasons to transition to a single-dose strategy. We discuss how a single-dose HPV vaccination strategy advances equity in three dimensions: vaccine equity, health equity, and gender equity. Adopting a single-dose strategy eases pressure on vaccine supply, lowers programme costs, and is easier to distribute.
Source: www.thelancet.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 13
The Pan-Lassa RDT is not currently recommended as a diagnostic or screening tool for suspected Lassa fever cases. Marked improvement in sensitivity and user friendliness is needed for the RDT to be adopted clinically. There remains an urgent need for better Lassa fever diagnostics to promote safety of in-hospital care and better disease outcomes in low-resource settings.
Source: www.thelancet.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 0Rapid diagnostic tests for Lassa fever: what do we aim for? - 8 day(s) ago
Lassa virus (LASV) is a high-consequence pathogen endemic to west Africa that causes annual outbreaks with substantial mortality. Besides transmission from the rodent reservoir to humans, human-to-human transmission can occur through contact with blood and other bodily fluids.1,2
Source: www.thelancet.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 17
All tested dosing regimens blocked some infections to a similar degree. Improved vaccine efficacy in participants infected during vaccination could suggest new strategies for highly efficacious malaria vaccine development and implementation.
Source: www.thelancet.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 59The Lancet Infectious Diseases, May 2024, Volume 24, Issue 5, Pages 437-556, e268-e343 - 22 day(s) ago
Peruse the current issue of The Lancet Infectious Diseases, a monthly journal covering international issues relevant to clinical infectious diseases specialists worldwide
Source: www.thelancet.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 2
With almost 775 million COVID-19 cases reported worldwide and 67% of the global population vaccinated with a complete primary series of a COVID-19 vaccine, the deadly pace of the pandemic has slowed down substantially.1 Sculpted by infection, immunisation, and subsequent reinfection due to immune escape of antigenically drifted virus variants, the evolving immunity of the population has provided an effective barrier to severe disease for most.2
Source: www.thelancet.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 11
SARS-CoV-2 viral clearance kinetics in symptomatic, vaccinated individuals accelerated substantially over 2 years of the pandemic, necessitating a change to how new SARS-CoV-2 antivirals are compared (ie, shortening the period of pharmacodynamic assessment). As of writing (October, 2023), antiviral efficacy in COVID-19 can be efficiently assessed in vivo using serial qPCRs from duplicate oropharyngeal swab eluates taken daily for 5 days after drug administration.
Source: www.thelancet.comCategories: General Medicine News, Infectious DiseaseTweet
Linked comment: Immune evasiveness of SARS-CoV-2 variants and vaccine selection https://t.co/znKlGlGdFV